Gene Therapy for Hemoglobinopathies (historically referred to as Thalagen)
Sickle Cell Disease and Beta Thalassemia
Pre-clinical / Early ClinicalActive
Key Facts
Indication
Sickle Cell Disease and Beta Thalassemia
Phase
Pre-clinical / Early Clinical
Status
Active
Company
About San Rocco Therapeutics
San Rocco Therapeutics is a private, pre-revenue biotech firm with a deep historical lineage in hemoglobinopathy research, originating from founder Patrick Girondi's personal mission in the 1990s. The company is advancing a gene therapy platform, leveraging a vector from renowned researcher Michel Sadelain, to treat Sickle Cell Disease and Beta Thalassemia. Based in Cambridge, USA, and with a European presence, it operates as a virtual R&D company, collaborating extensively with academic and clinical institutions to advance its programs, which appear to be in pre-clinical or early clinical stages.
View full company profile